Sponsors

Reportable events can be tricky: according to the regulations, not every unanticipated event should be submitted to the IRB.

Social media has emerged as a valuable tool for diverse stakeholders across the research community. Learn about the risks and benefits in this article.

What do the regulations say about unanticipated device effects and IRB reporting? In this blog, Advarra addresses unique requirements for medical device studies.

Participant compensation is often a complicated matter. This blog will shed light on what an IRB considers during its review.

Study-specific screening consent is a subtype of informed consent, which ensures a research participant understands of the research and its risks.

Oncology drugs in phase I trials are usually conducted on patients with cancer due to their inherent risk. Advarra IRB member Ran Goldman expands:

Stem cell clinics with unproven treatments are on the rise in the US. Learn how the FDA is working to bring new stem cell therapies under federal oversight.

Questions still remain about GDPR and its applications. Have you considered these six key questions to ask within your organization?

CBD, a non-psychoactive cannabinoid, is experiencing a massive surge in popularity, but clinical research lags behind in verifying effective uses.

On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum.

We have cancelled our webinar “After the Compliance Date: Revised Common Rule FAQs,” which was originally scheduled for February 28.

If your research must comply with the revised Common Rule, you’ll need to update the way you write ICFs to meet the new requirements.